Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Sofinnova Stories

2013-01-03 08:25:20

SAN FRANCISCO, Jan. 3, 2013 /PRNewswire/ -- Labrys Biologics Inc., a company focused on treatments for chronic migraine, today announced the completion of a $31 Million Series A financing from four leading venture capital firms, venBio, Canaan Partners, InterWest Partners, and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a Phase 2 ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P....

2012-12-04 08:27:56

SAINT PETERSBURG, Fla., Dec. 4, 2012 /PRNewswire/ -- Salveo Specialty Pharmacy, Inc., a specialty pharmacy company backed by Three Arch Partners, NewSpring Capital and Petra Capital Partners, today announces the completion of a second round of equity and debt funding, and its subsequent acquisition of Mission Road Pharmacy, a pharmacy based in Los Angeles, California focused on Oncology, HIV/AIDS, Hepatitis, Rheumatoid Arthritis and Mental Health therapies. The additional equity...

2012-12-04 00:21:36

WOBURN, Mass., Dec. 4, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today announced that the company has secured $20 million in a Series B financing round led by new investor, Novo Ventures. Flexion's existing investors, 5AM Ventures, Pfizer Venture Investments, Sofinnova Partners and Versant Ventures also participated in the financing. Proceeds will be used to fund late stage clinical development of the company's portfolio of intra-articular, sustained release therapies for the treatment...

2012-10-17 07:25:42

LA JOLLA, Calif., Oct. 17, 2012 /PRNewswire/ -- Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, today announced results of a Phase 1/2 trial of its lead investigational drug, ERSATTA(TM) in peripheral neuropathy. ERSATTA is the first once-weekly C-peptide therapy to target loss of nerve function and other vascular complications in type 1 diabetes patients. The successful 72 subject trial, which focused on safety, tolerability, and...

2012-06-25 22:21:47

OXFORD, England, June 26, 2012 /PRNewswire/ -- OBN, the not-for-profit business network which provides comprehensive support for bioscience businesses in the 'Golden Triangle' biocluster and beyond, is pleased to announce that it has established two new high level Advisory Panels. The two Boards draw on leading experts from across the industry and have been created in order to maintain OBN's leadership position in program development at BioTrinity, Europe's 3rd Largest Annual...

2012-05-14 06:23:51

ANN ARBOR, Mich., May 14, 2012 /PRNewswire-USNewswire/ -- The Michigan Venture Capital Association (MVCA) recently released its annual research report, which details investment activity across the state. The report also highlights venture capital activity in Michigan compared to other regions and the U.S. "The data collected in the MVCA research report show that Michigan's venture community is growing, both in size and deals," said Tim Petersen, MVCA board chair. "It's particularly...

2012-05-02 22:22:03

LUXEMBOURG, May 3, 2012 /PRNewswire/ -- Creabilis SA, a European biotechnology company specialising in the development of treatments for dermatology, inflammation and pain, announces today that Dr Simon Russell has been appointed as Chief Business Officer. Dr Russell joins Creabilis from Novartis Pharma AG where he held a number global strategic marketing roles and most recently Head of Global Marketing for ILARIS (canakinumab). He was previously Head of Strategic...

2012-04-25 06:24:14

OXFORD, England, April 25, 2012 /PRNewswire/ -- The rise of the corporate venture fund and the landscape for early-stage venture capital investing are emerging key themes at BioTrinity, the-premier European biopartnering and investment conference organised by OBN, the not-for-profit business network which provides comprehensive support for bioscience businesses in the Oxford and South-East England biocluster and beyond. The first day of the conference saw senior figures...

2012-03-28 02:29:31

SALT LAKE CITY, March 28, 2012 /PRNewswire/ -- Signal Peak Ventures and vSpring Capital, two leading venture capital firms in the Rocky Mountain region, today announced the combination of their partnerships. The combined partnership, which will operate under the Signal Peak Ventures name, will continue to manage the existing portfolios of the respective firms and make early-stage investments in the information technology and life sciences sectors within the Rocky Mountain States. Effective...

2012-02-22 06:00:00

MINNEAPOLIS, MN, Feb. 22, 2012 /PRNewswire/ - BioAmber Inc. has completed its Series C round of financing with net proceeds of $30 million. The financing was closed in two tranches; a first tranche of $20 million on November 4(th), 2011 with existing investors Naxos Capital, Sofinnova Partners, Mitsui & Co. Ltd. and the Cliffton Group, and a second tranche of $10 million on February 6(th), 2012 with specialty chemicals company LANXESS. All of BioAmber's Series B investors...